Patients with advanced hepatocellular carcinoma had a worse survival following progression if they developed new extrahepatic lesions as opposed to other types of progression, supporting the concept of post-progression survival and the influence of different patterns of progression, according to an analysis of the phase III RESORCE trial.
A combination regimen of pembrolizumab plus ramucirumab demonstrated modest activity in patients with previously treated gastric or gastroesophageal juncture cancer.
Scientists from the Sidney Kimmel Cancer Center at Thomas Jefferson University have pinpointed a survival protein for patients suffering from non-Hodgkin's lymphoma.
Researchers at Yale Cancer Center and Yale Medicine have identified the critical target of new immune-checkpoint therapies: subsets of immune cells called tissue resident memory (TRM) T cells. In the same research, scientists also found that individual metastatic cancer lesions contain unique sets of TRM cells.
To better understand how cancer initiates and spreads, Yale associate professor of pathology Qin Yan turned to the field of epigenetics, which examines changes in the expression of genes and proteins that do not affect the underlying genetic codes.
The regular use of aspirin lowers the risk for pancreatic cancer by almost 50 percent, a new study in China led by the Yale School of Public Health finds.
A new Yale study suggests that patients with a common form of lung cancer may still benefit from delayed chemotherapy started up to four months after surgery, according to the researchers.
Half of the patients in a Wisconsin Oncology Network (WON) clinical trial for a rare blood cancer are still in remission eight years after beginning treatment, according to new results of a follow-up to the study.
It was little more than 3 years ago that ibrutinib became the first Bruton tyrosine kinase (BTK) inhibitor to gain the FDA’s approval with a second-line indication for patients with mantle cell lymphoma.
In August 2016, the FDA approved pembrolizumab for patients with platinum-refractory squamous cell carcinoma of the head and neck. Not only was it the first immunotherapy approved for head and neck cancer (HNC), but it marked the first new drug approval for HNC in the United States in 20 years.
Keeping a medical practice strong and independent in today’s turbulent environment can be quite challenging.
Results from the randomized phase II HOVON89 trial showed that nearly 40% of patients with low intermediate-1 risk myelodysplastic syndrome who were refractory to erythropoietin and granulocyte-colony stimulating factor experienced hematologic improvement with erythroid response after being treated with lenalidomide monotherapy.
The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, welcomes Kenneth W. Hance, Ph.D., M.P.H., Director of Antibody Therapies, Immuno-Oncology & Combinations DPU at GlaxoSmithKline (GSK), as its first Visiting Professor from GSK at Wistar.
The BCL-2 inhibitor venetoclax (Venclexta) demonstrated activity in one-fifth of patients with heavily pretreated multiple myeloma.
Patients with myeloproliferative disorders have a high symptom burden that significantly affects emotional status, quality of life, and functional ability.
Patients with intermediate/high-risk myelofibrosis had improved survival when treated long term with the Janus kinase inhibitor ruxolitinib.
A third of patients with previously treated, high- and intermediate-risk myelofibrosis had objective responses to the investigational Second mitochondria-derived activator of caspases mimetic LCL161.
An analysis of c-MYC expression in relapsed myeloma identified subgroups of patients with improved response to the combination of an immunomodulator and a proteasome inhibitor.
Patients with newly diagnosed multiple myeloma had significant improvement in progression-free survival when treated with dual versus single autologous stem-cell transplant.
Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib (Jakafi) in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial.
Multiple myeloma has seen significant treatment advances over the past decade. In 2015 alone, the FDA approved 5 new agents or regimens for previously treated patients.
A subgroup analysis of the randomized MONALEESA-2 trial showed that patients with advanced HR-positive, HER2-negative breast cancer, and visceral metastases obtained a significant benefit from treatment with the CDK4/6 inhibitor ribociclib combined with letrozole.
A biomarker analysis of participants in a phase II breast cancer trial demonstrated potential for identifying tumor markers to predict susceptibility to specific therapies.
Patients with myelofibrosis and thrombocytopenia had significantly greater reductions in spleen volume and symptoms when treated with the multikinase inhibitor pacritinib, compared with the best available therapy.
Two thirds of patients with chronic lymphocytic leukemia (CLL) that progressed on B-cell receptor pathway inhibitors had objective responses to treatment with venetoclax, results of a small open-label trial showed.
Almost 80% of patients with treatment-refractory non-Hodgkin lymphoma had objective responses following treatment with KTE-C19, a chimeric antigen receptor T-cell therapy targeting CD19.
Scientists at the Sidney Kimmel Cancer Center have been able to validate the contemporary five-tiered Gleason Grade Grouping Using Population-based Data.
When combined with psychological counseling, a single dose of a mind-altering compound contained in psychedelic mushrooms significantly lessens mental anguish in distressed cancer patients for months at a time, according to results of a clinical trial led by researchers at NYU Langone Medical Center.
Dean F. Bajorin, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, discusses the standard chemotherapy approaches for patients with metastatic and muscle-invasive bladder cancer.
Younger patients with mantle cell lymphoma lived significantly longer and without disease progression or clinical events when they received rituximab maintenance therapy after stem cell transplantation, final results of a randomized trial showed.